Transgenic Mouse

转基因小鼠/胚胎干细胞共享资源自1993年以来一直存在，并从1995年范德比尔特-英格拉姆癌症中心（VICC）获得第一笔癌症中心支持基金以来，一直得到NCI的持续资助。在上一次竞争性更新时，该共享资源获得了“优秀”评级。该资源提供基因靶向、DNA原核显微注射、胚胎干细胞显微注射、辅助生殖以及精子和胚胎冷冻保存服务

The Transgenic Mouse/ES Cell Shared Resource has been in existence since 1993 and has received continuous funding from the NCI since the Vanderbilt-lngram Cancer Center (VICC) was awarded its first Cancer Center Support Grant in 1995. At the time of the last competitive renewal, this shared resource received an "Outstanding" rating. This resource provides gene targeting, DNA pronuclear microinjections, ES cell microinjections, assisted reproduction and both sperm and embryo cryopreservation services to members of the VICC. These services are essential for the generation, maintenance, and long-term storage of germline-altered mice. The resource continues to function in a multidisciplinary manner and has undergone several significant changes since the last competitive evaluation that have enabled it to continue to provide gene targeting and microinjection services at reasonable prices, to develop several new services, and to improve both its quality control and data management strategies. The Transgenic Mouse/ES Cell Shared Resource continues to offer services that remain in high demand and vital to the generation of new mouse models of cancer and other diseases. This will be critical as the gene-specific information from genome-wide cancer studies is translated to mouse models of human cancer. Moreover, the technology base that this resource supports is expected to be important in allowing Vanderbilt investigators to adapt to using of human pluripotent stem cells in the future.